Neurocrine Biosciences reports Q3 2026 revenue over $1 billion and raises INGREZZA sales guidance
Neurocrine Biosciences announced third‑quarter 2026 results showing total revenue of $1.1 billion, a 41% year‑over‑year increase. INGREZZA net product sales rose 17% to $801 million, while newer products CRENESSITY and VYKAT XR generated $211 million and $107 million respectively. The company lifted its full‑year INGREZZA sales guidance to $2.9 billion‑$2.925 billion and CEO Kyle Gano said the firm expects double‑digit volume growth in 2027 despite mid‑to‑high single‑digit pricing headwinds.
Why it matters
The higher revenue and raised guidance suggest stronger demand for Neurocrine’s portfolio, which could support the stock price. The company also signals that volume growth is expected to offset pricing pressure, a key factor for investors evaluating future earnings.
Key facts
- 1Total third‑quarter 2026 revenue was $1.1 billion, up 41% year‑over‑year. sec.gov
- 2INGREZZA net product sales were $801 million, a 17% increase year‑over‑year. sec.gov
- 3CRENESSITY net product sales were $211 million, a 115% increase year‑over‑year. sec.gov
- 4VYKAT XR net product sales were $107 million. sec.gov
- 5GAAP net income for the quarter was $207 million, and non‑GAAP earnings per share were $3.29. sec.gov
- 6Full‑year 2026 INGREZZA sales guidance was raised to $2.9 billion‑$2.925 billion. sec.gov
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.